231 related articles for article (PubMed ID: 21768330)
21. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
Guan H; Zhou Z; Gallick GE; Jia SF; Morales J; Sood AK; Corey SJ; Kleinerman ES
Mol Cancer Ther; 2008 Jul; 7(7):1807-16. PubMed ID: 18644993
[TBL] [Abstract][Full Text] [Related]
22. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Brenner JC; Feng FY; Han S; Patel S; Goyal SV; Bou-Maroun LM; Liu M; Lonigro R; Prensner JR; Tomlins SA; Chinnaiyan AM
Cancer Res; 2012 Apr; 72(7):1608-13. PubMed ID: 22287547
[TBL] [Abstract][Full Text] [Related]
23. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
[TBL] [Abstract][Full Text] [Related]
24. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
25. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
26. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
[TBL] [Abstract][Full Text] [Related]
27. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
28. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
29. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
30. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
32. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.
Braunreiter CL; Hancock JD; Coffin CM; Boucher KM; Lessnick SL
Cell Cycle; 2006 Dec; 5(23):2753-9. PubMed ID: 17172842
[TBL] [Abstract][Full Text] [Related]
33. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
34. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
35. [Ewing's tumours, genetic and cellular aspects].
Delattre O
Pathol Biol (Paris); 2008 Jul; 56(5):257-9. PubMed ID: 18485618
[TBL] [Abstract][Full Text] [Related]
36. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
37. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
39. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
40. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.
Owen LA; Lessnick SL
Cell Cycle; 2006 Sep; 5(18):2049-53. PubMed ID: 16969112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
